Protein misfolding causes devastating diseases that affect millions of people. Small-molecule correctors are a proven way to treat them, but they have mostly been developed for diseases where a few common mutations cover most patients. We design correctors to work across many mutations from the start, testing them in engineered human cells that carry the mutations patients have.
Our pipeline
Small-molecule medicines for genetic disease, cancer and other serious diseases.
An investigational oral corrector for retinitis pigmentosa.
Phase 1b/2 in patients with RHO-adRP
FDA Orphan Drug Designation for retinitis pigmentosa
Retinitis pigmentosa causes progressive vision loss and can lead to blindness. In RHO-adRP, one of the most common forms of RP with no approved treatment, misfolded rhodopsin mislocalizes within rod cells, accumulating to toxic levels. OCT-980 is designed to stabilize misfolded rhodopsin and restore rhodopsin trafficking.
Untreated, misfolded rhodopsin accumulates to toxic levels in the rod cell. OCT-980 is designed to bind and stabilize it, so it can fold and continue to its destination.
Misfolded rhodopsin can only be studied in living cells, so we engineered human cells that report whether a molecule restores rhodopsin trafficking.
We made and screened more than 250,000 molecules directly in those cells to design an oral, potent corrector that reaches the retina. During that campaign, low-potency early compounds became OCT-980.
Tested against every possible variant
RHO-adRP is caused by many different rhodopsin mutations. In our engineered-cell assays, OCT-980 rescues most misfolding rhodopsin variants.
One medicine needs to work across as many variants as possible, so we measured all 6,612 possible single amino-acid changes in rhodopsin, with and without OCT-980. Our complete map of the mistrafficking of rhodopsin is published in Science Advances.
Laboratory condition
Different mutations disrupt the same protein. Each square is one rhodopsin variant, measured in engineered human cells without and with OCT-980. Learn more about deep mutational scans
Lower traffickingHigher trafficking
No drug selected.
Improves retinal structure in animal models
In animal models, OCT-980 improves retinal structure and slows the loss of rod cells.
Without treatment, misfolded rhodopsin is mistrafficked within rod cells, and the photoreceptor layer thins. With OCT-980, more rhodopsin reaches its destination and more of the photoreceptor layer is preserved.
Healthy
Untreated
With OCT-980
Rhodopsin in the outer segmentsRhodopsin stuck in the ERCell nuclei
Retinal cross-sections from a preclinical animal model. Untreated, more rhodopsin is stuck in the endoplasmic reticulum (ER), where the cell folds new proteins, and less reaches the outer segments.
A better oral treatment, for more people with Fabry disease.
Fabry disease damages the kidneys, heart and nervous system, and today’s treatments leave much of that burden in place. We are building an oral corrector that stabilizes α‑galactosidase A without blocking its activity, aiming to treat new patients and better treat those already being treated.
Mutant p53, unable to bind DNAp53 bound to DNAOur moleculeDNA
p53-mutant cancers
Hit to Lead
Switch p53 back on in the cancers that disable it.
TP53 is the most frequently mutated gene in cancer, altered in about half of all tumors. We are building multi-variant correctors designed to restore mutant p53’s proper interaction with DNA, aimed at a class of mutations that affects many forms of cancer.
Built through experiments in living cells
Our platform connects engineered cellular assays, parallel chemistry and computational learning to guide the next experiments.